Potency and QC Lot-Release Testing Product Solutions

Providing Functional, MOA-based Bioassays with Superior Lot-to-lot Reproducibility

Cell-based potency assays are critical tools to measure the efficacy of a drug during stability and potency testing. Potency assays are initiated in the early drug development stage to measure the biologic's intended biological effect and mechanism of action (MOA) being analyzed. Quality control (QC) lot-release testing, intended for late-stage drug release programs, involves assays that ensure consistency with high lot-to-lot reproducibility. Given that the process of drug discovery and development is time consuming, complex, and expensive, implementing a physiologically relevant assay platform from the early development phase to late-stage drug release programs such as QC lot release can prove to be highly valuable.

Eurofins DiscoverX® develops qualified, MOA-reflective cell-based assays (bioassays) that are phase-appropriate and meet the requirements of specific therapeutic development stages, including potency and QC lot-release testing. These bioassays are derived from stable cell lines and provide a simple, thaw-and-use approach that alleviates assay passage-to-passage variability associated with cells derived from continuous cell culture. Packaged with ready-to-use cryopreserved cells, plates, and all the reagents and documents needed, Eurofins DiscoverX bioassay kits offer the ideal solution for your therapeutic development programs. These kits are rigorously tested to meet ICH (International Council for Harmonization) requirement guidelines and qualified with marketed biologic drugs or reference standards, allowing you to confidently de-risk your potency testing program and accelerate your therapeutic development timelines.

Product Highlights

  • Physiologically Relevant — Bioassays qualified with marketed biologic drugs or reference standards using ICH guidelines
  • Phase-appropriate Solutions – Complete ready-to-use, functional cell-based assay kits of unsurpassed quality for potency and QC lot-release testing
  • Deep Expertise – Over two decades of experience in developing cell-based assays to support your specific therapeutic development stage
  • Full Support – Dedicated team for end-to-end assay transfer and long-term support of your commercial release and stability programs at CRO/CDMO sites
Consider Eurofins DiscoverX’s custom development capabilities for custom cell lines, assays, & enzyme development.

Eurofins DiscoverX Provides Cell-based Assay Product Solutions and Full CRO/CDMO Support

Eurofins DiscoverX CRO/CDMO Site
Stable Cell Lines > Ready-to-Use Bioassay Format > Qualified Method with Marketed Drug > Assay Transfer Support to CRO/CDMO Site > Assay Validation for GMP Lot Release Testing >
  • MOA-Based Cell Lines
  • Passage Stability Tested
  • Established Functional Response
  • 800+ Cell Lines and Stable Cell Pools
  • High Assay Reproducibility
  • Easy-to-Perform Protocol
  • No Cell Culture / Passaging
  • Cost Effective for Long-Term
  • Easy-to-Transfer Between Sites
  • Large Lot Production
ICH-Based Assay Qualification
  • Accuracy
  • Precision
  • Range
  • Dilutional Linearity
  • Specificity
  • Parallelism
  • End-to-End Support for Successful Assay Transfer at CRO/CDMO Sites
  • Dedicated Team Helping with CRO/CDMO Assay Implementation
  • CRO/CDMO Performs
  • CRO/CDMO Implements Assay for QC Lot-Release Testing

Long-Term Support

  • Supply Agreements
  • Audit Ready with Full Traceability
  • Critical Reagents Management
  • Well Characterized Analytical Cell Banks

Eurofins DiscoverX offers the largest portfolio of cell lines and cell-based assays for characterization studies, potency testing in QC lot-release, neutralizing antibodies (NAbs) detection, and stability programs. Cell-based bioassay kits are easy to implement in any lab from pre-clinical development to QC lot release, and qualified with marketed biologic drugs or reference standards. Global technical support and field application scientist teams provide end-to-end assay transfer support for you at contract research and contract development and manufacturing organizations (CRO/CDMO). GMP = good manufacturing practices.

Global Programs using Eurofins DiscoverX Bioassays for Potency, Stability, and NAb Testing for Drug Release

Global Programs using Eurofins DiscoverX Bioassays for Potency, Stability, and NAb Testing for Drug Release

Choose from Industry’s Largest Portfolio of Ready-to-use Bioassays

Access the continually expanding portfolio of over 60 MOA-reflective, ready-to-use bioassay kits or consider Eurofins DiscoverX Custom Development Capabilities to meet your specific assay needs with the same level of robustness as off-the-shelf assays. With decades of cell-based assay development and cell line engineering expertise, utilize this service to generate custom bioassays or further screen and validate bioassays with your molecule using systematic qualification protocols.

MOA-reflective Bioassays

According to industry guidelines published by the US Federal Drug Administration (FDA), an MOA-reflective, physiologically-relevant assay is essential to accurately report a drug product’s potency and stability. Eurofins DiscoverX bioassays are specifically designed to measure the proximal molecular events occurring directly as a consequence of receptor activation, thus providing assay readouts that truly represent the MOA of the drug candidate. The target- or MOA-based bioassays are optimized with a reference ligand. These assays can be readily implemented in development programs for drug candidates (biologics or small molecules) that use the same MOA for the target.

Qualified Bioassays

Eurofins DiscoverX’s bioassay development strategy is driven by industry standards. The MOA-reflective, functional cell-based bioassays are developed and optimized following systematic qualification studies to evaluate key attributes defined by ICH Technical Requirements for Pharmaceuticals for Human Use and United States Pharmacopeia (USP) guidelines. These attributes include accuracy, precision, linearity, range, specificity, robustness, and stability-indicating properties that demonstrate consistency in assay performance and generate reliable measurements that can be correlated with the clinical outcomes of the drug candidate.

Qualified Bioassays

Obtain End-to-end Support for Assay Transfers to CRO/CDMO Sites for Your QC Lot Release Program

Eurofins DiscoverX’s global Field Application Scientist team provides extensive technical support and consultation with availability for onsite trouble shooting or training. For CRO/CDMOs, consider the Certification Program designed to qualify CRO/CDMO’s to run Eurofins DiscoverX’s bioassays.

Documentation Support

Eurofins DiscoverX is committed to delivering high-quality products for supporting drug development programs from discovery to lot release. The Eurofins DiscoverX Quality Management System has oversight by a Quality Assurance (QA) Manager and support by the company President. The bioassays contain QA-reviewed product documentation, including a lot-specific Certificate of Analysis, Batch Traceability records, Safety Data Sheets, Marker Rescue documents, and other biosafety documents to support regulatory filings.

Critical Reagents Management Programs

Eurofins DiscoverX has in place strategies for long-term product support, including a two-tiered analytical cell banking program that ensures uninterrupted supply of critical reagents (bioassay cells) for the life of your drug program. This program delivers long-term lot-to-lot reproducibility, reducing the burden for lot bridging studies, and provides flexible inventory management enabling customized production of large dedicated lots, flexible storage options, as well as customized shipment schedules. Learn more about this Cell Banks for Bioassay Program to ensure long-term assay reproducibility with the production of bioassay cells from dedicated, well-characterized, and established cell banks.

Additional programs including technology transfer are available to help with your commercialization risk mitigation strategy. Contact us to learn more.

Target Lists Products Target List

Comprehensive Eurofins DiscoverX product list to enable your drug discovery and development programs focused on checkpoint receptors, cytokine receptors/interleukins, cytotoxicity,…

Read More
Target Lists Cell-based Assays for Biologics Development Programs

Accelerate your biologics development from discovery to QC lot release with cell-based assays. Comprehensive list of bioassay kits, cell lines,…

Read More

Webinars Automating Functional Cell-based Bioassays: Assay Reproducibility and Performance for Potency Testing Programs

Throughout early discovery and particularly for market release, biologic drug candidates require mechanism-of-action (MOA)-based functional, cellular assays as characterisation tools…

Watch Now
Webinars Establishing Qualified Bioassays for Checkpoint Receptors to Implement in QC Lot Release: Case Studies on PD-1 and SIRPα

Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, which is often exploited…

Watch Now
Webinars Accelerate Biologics and Biosimilars Development: Case Studies Implementing Robust and Simple Potency Bioassays

A quantitative and robust bioassay that is reflective of the MOA of the drug is a critical component of any…

Watch Now
Webinars Functional Assays for the Development of Agonistic Abs for Immunotherapies

Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed…

Watch Now

Videos Custom Development Capabilities

Learn about Eurofins DiscoverX cell line engineering, assay development, and recombinant enzyme production custom capabilities. Find out more about cell…

Watch Now

Scientific Posters Advances in tools to compare potency, efficacy, safety & quality of follow-on biologics or biosimilars

Regulatory authorities define biosimilars as drugs that are “highly similar” to or “interchangeable” with an approved biologic. The lack of…

Read More
Scientific Posters Ready-to-use potency assays for anti-VEGF drugs such as Bevacizumab

Cell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…

Read More
Scientific Posters Ready-to-Use Potency Assays for Bevacizumab, Aflibercept, & Ranibizumab

Cell-based bioassays often pose a hurdle during a rapidly moving biologics development program. High standards for assay accuracy, precision, reproducibility…

Read More
Scientific Posters Robust and Simple Potency and NAb Bioassays for Avastin® Biosimilar Development

One of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…

Read More
Scientific Posters Validated Bioassays for Potency, Stability and Lot Release Testing of Biopharmaceuticals

Biologics represents one of the fastest growing classes of biopharmaceutical molecules today. One of the major bottlenecks in the development…

Read More
Scientific Posters Novel, Improved Cell-Based Assays to Enable Immunotherapy Drug Development for Checkpoint Receptors

Regulation of immune responses is tightly controlled through a balance of co-stimulatory and inhibitory checkpoint receptors, often exploited by many…

Read More
Scientific Posters Rapidly Develop Simple Potency Assays for Interleukins & Their Receptors

Ligand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…

Read More

Blogs & Articles Accelerating Development of GLP-1 & GLP-2 Therapeutics with Validated Bioassays

Glucagon-like peptides, GLP-1 & GLP-2, are well-researched, metabolically significant peptide hormones secreted from the L-cells of the small intestine in…

Read More
Blogs & Articles Evaluate GLP-1R Targeted Therapeutics using First-to-Market Semaglutide Qualified GLP-1R Bioassay

Glucagon-Like Peptide-1 (GLP-1), a member of the glucagon-secretin peptide family, is secreted from L-cells of the small intestine and binds…

Read More
Blogs & Articles Accelerating Biologics Therapeutics with Bioassays: An In-Depth Discussion on the Essence of Bioassays Implemented for Drug Development

Eurofins DiscoverX, in conjunction with Drug Target Review, sponsored and moderated a Bioassay roundtable discussion webinar with group leaders from…

Read More
Blogs & Articles Accelerating Cytokine Drug Discovery and QC Lot Release Testing with Qualified, Functional Cell-Based Assays

Cytokines and their receptors have emerged as major drug targets for inflammatory and autoimmune diseases, allergies, and, more recently, in…

Read More
Blogs & Articles Use of Automated Functional, Cell-Based Bioassays

Importance in Drug Discovery & Development for Quality Testing Programs. GPCR CNR1 Bioassay example.

Read More
Blogs & Articles Eliminating Donor Variability in ADCC Assays – Implementation in QC Lot Release

Class I therapeutic antibodies achieve their clinical efficacy by binding to their target antigen and through Fragment crystallisable region (Fc)…

Read More
Blogs & Articles Accelerating Biologics Development Programs With Phase-Appropriate Ready-To-Use Potency Bioassays

Biological activity of a biotherapeutic is a Critical Quality Attribute (CQA), which needs to be accurately measured by an appropriate…

Read More

Publications The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab

Several Bevacizumab products are approved for clinical use, with many others in late-stage clinical development worldwide. To aid the harmonization…

Read More

Brochures & Flyers Eurofins DiscoverX – Delivering Solutions from Discovery to Market

Products & Custom Development Capabilities.

Read More
Brochures & Flyers Insights into Immunotherapeutic Discovery & Development

Discover valuable insights on breakthroughs, innovative strategies, and cell-based approaches for immunotherapeutic discovery and development.

Read More

eBooks Insights into Immunotherapeutic Discovery & Development

Discover valuable insights on breakthroughs, innovative strategies, and cell-based approaches for immunotherapeutic discovery and development.

Read More
Bioassays for Biologics

Ready-to-use kits for biologics characterization, MOA confirmation, NAbs detection, stability studies, & potency testing

Read More
CDMO/CRO Certification Program for Cell-Based Assays

Program designed to qualify CRO/CDMOs to run Eurofins DiscoverX bioassays for client downstream therapeutic efforts

Read More
Cell Banks for Bioassays

Ensure long-term assay reproducibility with the production of bioassay cells — critical reagents for cell banks

Read More
Cell Lines and Primary Cells

Stable cell lines, cell pools, frozen cells, & primary effector cells for a broad range of target classes

Read More
Custom Capabilities

Custom cell lines, kits, assays, & protein development capabilities optimized to fit your requirements

Read More